(Circulation. 1999;99:786-792.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Neurohumoral Prediction of Benefit From Carvedilol in Ischemic Left Ventricular Dysfunction
From the Department of Medicine, Christchurch Cardioendocrine Group, Christchurch School of Medicine, Christchurch, New Zealand.
Correspondence to Prof A. Mark Richards, Christchurch Cardioendocrine Group, Department of Medicine, Christchurch School of Medicine, PO Box 4345, Christchurch, New Zealand. E-mail bgriffin{at}chmeds.ac.nz
Background—Plasma neurohormones were analyzed for prediction of adverse outcomes and response to treatment in 415 patients with ischemic left ventricular dysfunction randomly assigned to receive carvedilol or placebo.
Methods and Results—Atrial natriuretic peptide, brain natriuretic peptide (BNP), or norepinephrine (NE) levels above the group median were associated with increased mortality rates and heart failure. On multivariate analysis, both BNP and NE interacted with treatment to predict death or heart failure independent of age, New York Heart Association class, and left ventricular ejection fraction. For placebo, supramedian levels of BNP were associated with 3-fold the mortality rate of inframedian levels (20/104; 19% vs 6/99; 6%; P<0.01). For carvedilol, mortality rate was comparable in these 2 subgroups (12/109; 11% vs 8/94; 9%; NS). Corresponding rates for heart failure were 29/104 (28%) versus 3/99 (3%; P<0.001) for placebo and 16/109 (15%) versus 7/94 (7%; NS) for carvedilol. High NE levels did not predict additional benefit from carvedilol, which significantly reduced heart failure admissions only in those with NE levels below the median (13.1% to 4.0%; P<0.01). In the 23% of the study population with supramedian BNP but inframedian levels of NE, carvedilol reduced hospital admission with heart failure by >90% (P<0.001).
Conclusions—Carvedilol reduced mortality rates and heart failure in those with higher pretreatment BNP levels but lesser activation of plasma NE. Neurohumoral profiling may guide introduction of ß-blockade in heart failure.
Key Words: heart failure • natriuretic peptides • norepinephrine
This article has been cited by other articles:
 |
|
 |
|
  J P Kaski, M T Tome-Esteban, S Mead-Regan, A Pantazis, J Marek, J E Deanfield, W J McKenna, and P M Elliott B-type natriuretic peptide predicts disease severity in children with hypertrophic cardiomyopathy Heart, October 1, 2008; 94(10): 1307 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Maisel, C. Mueller, K. Adams Jr., S. D. Anker, N. Aspromonte, J. G.F. Cleland, A. Cohen-Solal, U. Dahlstrom, A. DeMaria, S. Di Somma, et al. State of the art: Using natriuretic peptide levels in clinical practice Eur J Heart Fail, September 1, 2008; 10(9): 824 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R J Hillock, C M Frampton, T G Yandle, R W Troughton, J G Lainchbury, and A M Richards B-type natriuretic peptide infusions in acute myocardial infarction Heart, May 1, 2008; 94(5): 617 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Whalley, S. P. Wright, A. Pearl, G. D. Gamble, H. J. Walsh, M. Richards, and R. N. Doughty Prognostic role of echocardiography and brain natriuretic peptide in symptomatic breathless patients in the community Eur. Heart J., February 2, 2008; 29(4): 509 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Rose and W. R. Giles Natriuretic peptide C receptor signalling in the heart and vasculature J. Physiol., January 15, 2008; 586(2): 353 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Olsson, K. Swedberg, J. G.F. Cleland, P. A. Spark, M. Komajda, M. Metra, C. Torp-Pedersen, W. J. Remme, A. Scherhag, P. Poole-Wilson, et al. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a {beta}-blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial Eur J Heart Fail, August 1, 2007; 9(8): 795 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Jourdain, G. Jondeau, F. Funck, P. Gueffet, A. Le Helloco, E. Donal, J. F. Aupetit, M. C. Aumont, M. Galinier, J. C. Eicher, et al. Plasma Brain Natriuretic Peptide-Guided Therapy to Improve Outcome in Heart Failure: The STARS-BNP Multicenter Study J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1733 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Williams, C. E. Handler, R. Akram, C. J. Smith, C. Das, J. Smee, D. Nair, C. P. Denton, C. M. Black, and J. G. Coghlan Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension Eur. Heart J., June 2, 2006; 27(12): 1485 - 1494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Mueller, K. Laule-Kilian, C. Schindler, T. Klima, B. Frana, D. Rodriguez, A. Scholer, M. Christ, and A. P. Perruchoud Cost-effectiveness of B-Type Natriuretic Peptide Testing in Patients With Acute Dyspnea. Arch Intern Med, May 22, 2006; 166(10): 1081 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schnabel, E. Lubos, H. J. Rupprecht, C. Espinola-Klein, C. Bickel, K. J. Lackner, F. Cambien, L. Tiret, T. Munzel, and S. Blankenberg B-Type Natriuretic Peptide and the Risk of Cardiovascular Events and Death in Patients With Stable Angina: Results From the AtheroGene Study J. Am. Coll. Cardiol., February 7, 2006; 47(3): 552 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Richards, M. G. Nicholls, E. A. Espiner, J. G. Lainchbury, R. W. Troughton, J. Elliott, C. M. Frampton, I. G. Crozier, T. G. Yandle, R. Doughty, et al. Comparison of B-Type Natriuretic Peptides for Assessment of Cardiac Function and Prognosis in Stable Ischemic Heart Disease J. Am. Coll. Cardiol., January 3, 2006; 47(1): 52 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Morrow, J. A. de Lemos, M. A. Blazing, M. S. Sabatine, S. A. Murphy, P. Jarolim, H. D. White, K. A. A. Fox, R. M. Califf, E. Braunwald, et al. Prognostic Value of Serial B-Type Natriuretic Peptide Testing During Follow-up of Patients With Unstable Coronary Artery Disease JAMA, December 14, 2005; 294(22): 2866 - 2871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Avgeropoulou, I. Andreadou, S. Markantonis-Kyroudis, M. Demopoulou, P. Missovoulos, A. Androulakis, and I. Kallikazaros The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine Eur J Heart Fail, August 1, 2005; 7(5): 882 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A.H. Stewart Broader indications for B-type natriuretic peptide testing in coronary artery disease Eur. Heart J., February 1, 2005; 26(3): 207 - 209. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Hartmann, M. Packer, A. J.S. Coats, M. B. Fowler, H. Krum, P. Mohacsi, J. L. Rouleau, M. Tendera, A. Castaigne, S. D. Anker, et al. Prognostic Impact of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure: A Substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial Circulation, September 28, 2004; 110(13): 1780 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kokubo, S. Miyagawa-Tomita, H. Tomimatsu, Y. Nakashima, M. Nakazawa, Y. Saga, and R. L. Johnson Targeted Disruption of hesr2 Results in Atrioventricular Valve Anomalies That Lead to Heart Dysfunction Circ. Res., September 3, 2004; 95(5): 540 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Menezes Falcao, F. Pinto, L. Ravara, and P. A. van Zwieten BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction Journal of Renin-Angiotensin-Aldosterone System, September 1, 2004; 5(3): 121 - 129. [Abstract] [PDF]
|
|
|
|
|
|
R. J. Rodeheffer Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004? J. Am. Coll. Cardiol., August 18, 2004; 44(4): 740 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Januzzi, A. S. Maisel, R. W. Troughton, A. M. Richards, T. G. Yandle, M. G. Nicholls, T. Nishikimi, H. Matsuoka, and M. Packer Routine Measurement of Natriuretic Peptide to Guide the Diagnosis and Management of Chronic Heart Failure * Response Circulation, June 29, 2004; 109(25): e325 - e326. [Full Text] [PDF]
|
|
|
|
|
|
M. Richards and R. W. Troughton NT-proBNP in heart failure: therapy decisions and monitoring Eur J Heart Fail, March 15, 2004; 6(3): 351 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Givertz and E. Braunwald Neurohormones in heart failure: predicting outcomes, optimizing care Eur. Heart J., February 2, 2004; 25(4): 281 - 282. [Full Text] [PDF]
|
|
|
|
|
|
R. Latini, S. Masson, I. Anand, M. Salio, A. Hester, D. Judd, S. Barlera, A. P Maggioni, G. Tognoni, J. N Cohn, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT Eur. Heart J., February 2, 2004; 25(4): 292 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. de Denus, C. Pharand, and D. R. Williamson Brain Natriuretic Peptide in the Management of Heart Failure: The Versatile Neurohormone Chest, February 1, 2004; 125(2): 652 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kjaer, J. Appel, P. Hildebrandt, and C. L. Petersen Basal and exercise-induced neuroendocrine activation in patients with heart failure and in normal subjects Eur J Heart Fail, January 1, 2004; 6(1): 29 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ishii, W. Cui, F. Kitagawa, T. Kuno, Y. Nakamura, H. Naruse, Y. Mori, T. Ishikawa, Y. Nagamura, T. Kondo, et al. Prognostic Value of Combination of Cardiac Troponin T and B-Type Natriuretic Peptide after Initiation of Treatment in Patients with Chronic Heart Failure Clin. Chem., December 1, 2003; 49(12): 2020 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.R Cowie, P Jourdain, A Maisel, U Dahlstrom, F Follath, R Isnard, A Luchner, T McDonagh, J Mair, M Nieminen, et al. Clinical applications of B-type natriuretic peptide (BNP) testing Eur. Heart J., October 1, 2003; 24(19): 1710 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Fisher, C Berry, L Blue, J J Morton, and J McMurray N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure Heart, August 1, 2003; 89(8): 879 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Richards, M. G. Nicholls, E. A. Espiner, J. G. Lainchbury, R. W. Troughton, J. Elliott, C. Frampton, J. Turner, I. G. Crozier, and T. G. Yandle B-Type Natriuretic Peptides and Ejection Fraction for Prognosis After Myocardial Infarction Circulation, June 10, 2003; 107(22): 2786 - 2792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ruskoaho Cardiac Hormones as Diagnostic Tools in Heart Failure Endocr. Rev., June 1, 2003; 24(3): 341 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bozkurt and D. L. Mann Use of Biomarkers in the Management of Heart Failure: Are We There Yet? Circulation, March 11, 2003; 107(9): 1231 - 1233. [Full Text] [PDF]
|
|
|
|
|
|
B. A. Groenning, J. C. Nilsson, P. R. Hildebrandt, A. Kjaer, T. Fritz-Hansen, H. B.W. Larsson, and L. Sondergaard Neurohumoral prediction of left-ventricular morphologic response to {beta}-blockade with metoprolol in chronic left-ventricular systolic heart failure Eur J Heart Fail, October 1, 2002; 4(5): 635 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. McGeoch, J. Lainchbury, G.I. Town, L. Toop, E. Espiner, and A.M. Richards Plasma brain natriuretic peptide after long-term treatment for heart failure in general practice Eur J Heart Fail, August 1, 2002; 4(4): 479 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hulsmann, R. Berger, B. Sturm, A. Bojic, W. Woloszczuk, J. Bergler-Klein, and R. Pacher Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure Eur. Heart J., June 1, 2002; 23(11): 886 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Maisel B-Type Natriuretic Peptide Levels: Diagnostic and Prognostic in Congestive Heart Failure: What's Next? Circulation, May 21, 2002; 105(20): 2328 - 2331. [Full Text] [PDF]
|
|
|
|
|
|
R. Berger, M. Huelsman, K. Strecker, A. Bojic, P. Moser, B. Stanek, and R. Pacher B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure Circulation, May 21, 2002; 105(20): 2392 - 2397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. S. Anand, V. G. Florea, and L. Fisher Surrogate end points in heart failure J. Am. Coll. Cardiol., May 1, 2002; 39(9): 1414 - 1421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.A de Boer and D.J van Veldhuisen Polypharmacy in chronic heart failure: practical issues regarding the use of angiotensin-converting enzyme inhibitors, beta-blockers and other drugs Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D111 - D116. [Abstract] [PDF]
|
|
|
|
|
|
J.o. Koglin, S. Pehlivanli, M. Schwaiblmair, M. Vogeser, P. Cremer, and W. vonScheidt Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1934 - 1941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Stanek, B. Frey, M. Hulsmann, R. Berger, B. Sturm, J. Strametz-Juranek, J. Bergler-Klein, P. Moser, A. Bojic, E. Hartter, et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction J. Am. Coll. Cardiol., August 1, 2001; 38(2): 436 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.R Kalra, S.D Anker, A.D Struthers, and A.J.S Coats The role of C-type natriuretic peptide in cardiovascular medicine Eur. Heart J., June 2, 2001; 22(12): 997 - 1007. [PDF]
|
|
|
|
|
|
A. M. Richards, R. Doughty, M. G. Nicholls, S. MacMahon, N. Sharpe, J. Murphy, E. A. Espiner, C. Frampton, T. G. Yandle, and for the Australia-New Zealand Heart Failure Group Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1781 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. de Boer, H.-M. J. Siebelink, R. A. Tio, F. Boomsma, and D. J. van Veldhuisen Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure Eur J Heart Fail, June 1, 2001; 3(3): 331 - 333. [Full Text] [PDF]
|
|
|
|
|
|
V. Cheng, R. Kazanagra, A. Garcia, L. Lenert, P. Krishnaswamy, N. Gardetto, P. Clopton, and A. Maisel A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study J. Am. Coll. Cardiol., February 1, 2001; 37(2): 386 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Oxenham and N. Sharpe Prognostic stratification in heart failure: what's the point? Eur. Heart J., November 2, 2000; 21(22): 1815 - 1816. [PDF]
|
|
|
|
|
|
A. K. Agarwal, P. Venugopalan, C. Woodhouse, and D. de Bono Catecholamine levels in heart failure due to dilated cardiomyopathy and their relationship to the severity of heart failure Eur J Heart Fail, September 1, 2000; 2(3): 261 - 263. [Full Text] [PDF]
|
|
|
|
|
|
M. R COWIE BNP: soon to become a routine measure in the care of patients with heart failure? Heart, June 1, 2000; 83(6): 617 - 618. [Full Text]
|
|
|
|
|
|
T. Stefanec Endothelial Apoptosis: Could It Have a Role in the Pathogenesis and Treatment of Disease? Chest, March 1, 2000; 117(3): 841 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Feldman and C. McTiernan New Insight Into the Role of Enhanced Adrenergic Receptor-Effector Coupling in the Heart Circulation, August 10, 1999; 100(6): 579 - 582. [Full Text] [PDF]
|
|